In 2013, they showed that the inhibition of eIF5A2 by knockdown or N1-guanyl-1,7-diaminoheptane treatment prevented EMT and downstream doxorubicin resistance in hepatocellular carcinoma (HCC) [96]. This evidence concerns the gene EIF5A2 and hepatocellular carcinoma.